Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Contributed by: Business Wire

Logo

Tags

Health

Clinical Trials

Research

Pharmaceutical

Science

Biotechnology

Gilead, Multi-Target Antibody Collaboration

More Like This

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

(Graphic: Business Wire)

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform

Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

Figure 1. Biocytogen’s RenNano® Platform Genetic Engineering Strategy (Source: https://biocytogen.com/antibody-drug-development/rennano）

Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing